Peptide therapeutics: current status and future directions.

By K. Fosgerau, T. Hoffmann. Drug Discovery Today, 2015

2,650 citations recorded by the source corpus.

Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated. Consequently, there is an increased interest in peptides in pharmaceutical research and development (R&D), and approximately 140 peptide therapeutics are currently being evaluated in clinical trials. Given that the low-hanging fruits in the form of obvious peptide targets have already been picked, it has now become necessary to explore new routes beyond traditional peptide design. Examples of such approaches are multifunctional and cell penetrating peptides, as well as peptide drug conjugates. Here, we discuss the current status, strengths, and weaknesses of peptides as medicines and the emerging new opportunities in peptide drug design and development.

Subfields: Molecular Biology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/4191d3d5f2d6586fe77d02b03193286d4e49ea59

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Radiology, Nuclear Medicine and Imaging

Citations in the corpus

Alternatives to antibiotics for maximizing growth performance and feed efficiency in poultry: a review (2017, background): “To date, over 2600 endogenous AMPs have been isolated and many more synthetic analogues were reported in various publications (http://aps.unmc.edu/AP/main.php; Fosgerau and Hoffmann, 2015).”
A Comprehensive Review on Current Advances in Peptide Drug Development and Design (2019, background): “Peptide drugs have two major drawbacks: Their in vivo instability and membrane impermeability [15].”
Therapeutic peptides: current applications and future directions (2022, background): “High serum fasting peptide YY (3-36) is associated with obesity-associated insulin resistance and type 2 diabetes.”
HPEPDOCK: a web server for blind peptide–protein docking based on a hierarchical algorithm (2018, background): “Therefore, determining the structure of protein–peptide complexes involved in these interactions is crucial for understanding the molecular mechanism and thus modulating the protein–protein interactions for therapeutic purpose (3,4).”
Structure-Based Prototype Peptides Targeting the Pseudomonas aeruginosa Type VI Secretion System Effector as a Novel Antibacterial Strategy (2017, background): “…the TplE “L” peptide must access the periplasm to disrupt the TplE-TplEi interaction, which could prove difficult, although cell-penetrating peptides (CPPs) attached to the TplE “L” peptide could potentially overcome this drawback to provide a novel therapeutic agent (Fosgerau and Hoffmann, 2015).”
Cellular Senescence: Aging, Cancer, and Injury. (2019, background): “However, therapeutic peptides have some significant drawbacks related to their stability and short half-life (123).”
Drugging the ‘undruggable’ cancer targets (2017, positive): “…oligonucleotides in nanoparticles 44 ), others are tweaking the ubiquitin system to hijack the degradation machinery and target specific cancer drivers 45 , and some are developing small and large peptides to interfere with PPIs and overcome the limitations of small interacting surfaces 46 .”
PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex (2016, background): “Peptides are a category of compounds that meets increasing interest as candidate therapeutics (1), and motivates numerous efforts.”
Bioactive peptides: A review (2017, background): “More than 60 peptide drugs have reached the market for the benefit of patients and approximately 140 peptide therapeutics are currently being evaluated in clinical trials (Fosgerau and Hoffmann, 2015).”